News
Merck & Company, Inc. (NYSE:MRK) is one of the high-margin pharma stocks to buy now. Jefferies has raised its price target on ...
Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib ...
Dr. Ma discussed key findings that have been shared so far this year on the topic of evolving treatment strategies for ...
Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...
3d
PHILADELPHIA.Today on MSNWSJ: Merck Makes $10 Billion Move as Keytruda Patent Expiration NearsMerck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...
Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a ...
States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...
Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how long-term LEAP-002 data provides critical reassurance around Lenvima’s durability and safety in treating ...
Merck & Co., Inc. (NYSE:MRK), one of the largest pharmaceutical companies in the world, has lost 15% year-to-date on the ...
Merck is tackling its looming “Keytruda cliff” with a bold $10 billion acquisition of Verona Pharma. The deal brings ...
Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...
Delhi has long stood as a beacon of modern healthcare. The national capital is home to gleaming hospitals, internationally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results